This company has been marked as potentially delisted and may not be actively trading. Anchiano Therapeutics (ANCN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ANCN vs. WHWK, OSTX, ATNM, NBRV, AADI, EGRX, PYRGF, NNVC, TAOX, and IBIOShould you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), Eagle Pharmaceuticals (EGRX), PyroGenesis Canada (PYRGF), NanoViricides (NNVC), Synaptogenix (TAOX), and iBio (IBIO). Anchiano Therapeutics vs. Its Competitors Whitehawk Therapeutics OS Therapies Actinium Pharmaceuticals Nabriva Therapeutics Aadi Bioscience Eagle Pharmaceuticals PyroGenesis Canada NanoViricides Synaptogenix iBio Anchiano Therapeutics (NASDAQ:ANCN) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability. Does the media refer more to ANCN or WHWK? In the previous week, Whitehawk Therapeutics had 1 more articles in the media than Anchiano Therapeutics. MarketBeat recorded 1 mentions for Whitehawk Therapeutics and 0 mentions for Anchiano Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.91 beat Anchiano Therapeutics' score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Anchiano Therapeutics Neutral Whitehawk Therapeutics Very Positive Is ANCN or WHWK more profitable? Whitehawk Therapeutics has a net margin of 99.42% compared to Anchiano Therapeutics' net margin of 0.00%. Anchiano Therapeutics' return on equity of 36.08% beat Whitehawk Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Anchiano TherapeuticsN/A 36.08% 27.40% Whitehawk Therapeutics 99.42%-75.99%-68.57% Do institutionals and insiders have more ownership in ANCN or WHWK? 9.1% of Anchiano Therapeutics shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 6.9% of Anchiano Therapeutics shares are held by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better valuation and earnings, ANCN or WHWK? Anchiano Therapeutics has higher earnings, but lower revenue than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnchiano TherapeuticsN/AN/A-$27.12M-$3.46-0.82Whitehawk Therapeutics$25.98M3.54-$63.69M-$0.06-32.50 Which has more volatility & risk, ANCN or WHWK? Anchiano Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Do analysts recommend ANCN or WHWK? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anchiano Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Whitehawk Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryWhitehawk Therapeutics beats Anchiano Therapeutics on 8 of the 13 factors compared between the two stocks. Get Anchiano Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANCN vs. The Competition Export to ExcelMetricAnchiano TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.92M$852.53M$5.70B$10.27BDividend YieldN/A4.84%5.72%4.60%P/E Ratio18.801.1975.8626.51Price / SalesN/A26.62491.12165.50Price / CashN/A19.5625.8129.89Price / Book1.406.6612.846.32Net Income-$27.12M-$4.13M$3.28B$270.51M Anchiano Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANCNAnchiano TherapeuticsN/A$2.82-7.0%N/A+69.9%$20.92MN/A18.8016WHWKWhitehawk Therapeutics1.1759 of 5 stars$1.80+0.6%N/AN/A$84.36M$25.98M-30.0021OSTXOS Therapies2.2243 of 5 stars$2.19-2.2%$18.00+721.9%-36.0%$69.30MN/A-2.77N/AATNMActinium Pharmaceuticals2.215 of 5 stars$1.60flat$4.50+181.3%-12.9%$49.91MN/A-1.1530NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070AADIAadi BioscienceN/A$1.79-1.6%N/A+10.6%$44.21M$25.07M-0.7940EGRXEagle PharmaceuticalsN/A$3.21+5.9%N/A-13.6%$41.69M$257.55M0.00100Gap DownPYRGFPyroGenesis CanadaN/A$0.18-6.0%N/A-68.7%$35.11M$9.14M-2.9390Gap UpNNVCNanoViricides0.2161 of 5 stars$1.46+1.4%N/A-9.9%$23.47MN/A-2.0320Gap UpTAOXSynaptogenix0.0709 of 5 stars$6.24-0.5%N/AN/A$21.86MN/A-0.314Positive NewsIBIOiBio1.6767 of 5 stars$0.83-2.6%$5.00+500.4%-53.6%$16.80M$375K-0.48100Short Interest ↑ Related Companies and Tools Related Companies WHWK Alternatives OSTX Alternatives ATNM Alternatives NBRV Alternatives AADI Alternatives EGRX Alternatives PYRGF Alternatives NNVC Alternatives TAOX Alternatives IBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANCN) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anchiano Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anchiano Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANCN Stock Alerts